LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer

American Journal of Translational Research

Volumn 8, Issue 11, 2016, Pages 5025-5034

  Huang, Chengsuo ^a   Liu, Shuguang ^a   Wang, Huijun ^a   Zhang, Zicheng ^a   Yang, Qing ^b   Gao, Fang ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Biomarker; lncRNA; PVT1; SCLC

Indexed keywords

LONG UNTRANSLATED RNA; PEPTIDES AND PROTEINS; PROTEIN PVT1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MTT ASSAY; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SMALL CELL LUNG CANCER; TUMOR GROWTH;

EID: 84999018401     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
3. Herbst RS, Heymach JV and Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
5. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW and Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
6. Pillai RN and Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol 2014; 41: 133-142.
7. Sher T, Dy GK and Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 355-367.
8. Ma M, Wang M, Xu Y, Hu K, Liu H, Li L, Zhong W, Zhang L, Zhao J and Wang H. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute]. Zhongguo Fei Ai Za Zhi 2014; 17: 8-14.
9. Sang H, Liu H, Xiong P and Zhu M. Long non-coding RNA functions in lung cancer. Tumour Biol 2015; 36: 4027-4037.
10. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K and Akimitsu N. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 2010; 584: 4575-4580.
11. Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R and Muller-Tidow C. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011; 6: 1984-1992.
12. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A and Prasanth KV. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013; 9: e1003368.
13. Ono H, Motoi N, Nagano H, Miyauchi E, Ushijima M, Matsuura M, Okumura S, Nishio M, Hirose T, Inase N and Ishikawa Y. Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Med 2014; 3: 632-642.
14. Zhuang Y, Wang X, Nguyen HT, Zhuo Y, Cui X, Fewell C, Flemington EK and Shan B. Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen. J Hematol Oncol 2013; 6: 35.
15. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX and De W. The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer 2013; 13: 464.
16. Chen B, Yu M, Chang Q, Lu Y, Thakur C, Ma D, Yi Z and Chen F. Mdig de-represses H19 large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3 and heterochromatin. Oncotarget 2013; 4: 1427-1437.
17. Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, Xie WP and Hou YY. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 2013; 13: 461.
18. Han L, Kong R, Yin DD, Zhang EB, Xu TP, De W and Shu YQ. Low expression of long noncoding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. Med Oncol 2013; 30: 694.
19. Zeidler R, Joos S, Delecluse HJ, Klobeck G, Vuillaume M, Lenoir GM, Bornkamm GW and Lipp M. Breakpoints of Burkitt’s lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC. Genes Chro-mosomes Cancer 1994; 9: 282-287.
20. Colombo T, Farina L, Macino G and Paci P. PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int 2015; 2015: 304208.
21. Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS and Feng XJ. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol 2014; 7: 6929-6935.
22. Cui D, Yu CH, Liu M, Xia QQ, Zhang YF and Jiang WL. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer. Tumour Biol 2016; 37: 4127-34.
23. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
24. Li L, Zhang L, Zhang Y and Zhou F. Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. Biomed Pharmacother 2015; 72: 109-112.
25. Ponting CP, Oliver PL and Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-641.
26. Webb E, Adams JM and Cory S. Variant (6; 15) translocation in a murine plasmacytoma occurs near an immunoglobulin kappa gene but far from the myc oncogene. Nature 1984; 312: 777-779.
27. Cory S, Graham M, Webb E, Corcoran L and Adams JM. Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the c-myc oncogene. EMBO J 1985; 4: 675-681.
28. Zeng C, Yu X, Lai J, Yang L, Chen S and Li Y. Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proli-feration in acute promyelocytic leukemia. J Hematol Oncol 2015; 8: 126.
29. Ding C, Yang Z, Lv Z, Du C, Xiao H, Peng C, Cheng S, Xie H, Zhou L, Wu J and Zheng S. Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol Lett 2015; 9: 955-963.
30. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, Yang N, Zhou WP, Li WL, Li W and Sun SH. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 2014; 60: 1278-1290.
31. Zhou Q, Chen J, Feng J and Wang J. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol 2016; 37: 3105-13.
32. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M and Mimori K. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2014; 110: 164-171.
33. Zhuang C, Li J, Liu Y, Chen M, Yuan J, Fu X, Zhan Y, Liu L, Lin J, Zhou Q, Xu W, Zhao G, Cai Z and Huang W. Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget 2015; 6: 41194-41203.
34. Kong R, Zhang EB, Yin DD, You LH, Xu TP, Chen WM, Xia R, Wan L, Sun M, Wang ZX, De W and Zhang ZH. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 2015; 14: 82.
35. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A and Wistuba II. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol 2014; 9: 998-1007.
36. [36] You L, Chang D, Du HZ and Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun 2011; 407: 1-6.
37. Liu E, Liu Z and Zhou Y. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol 2015; 8: 3803-3810.